Rivaroxaban: Difference between revisions
No edit summary |
(Added AF main page link to See Also) |
||
| (13 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Anticoagulant, Factor Xa Inhibitor | *Type: [[Anticoagulant]], Factor Xa Inhibitor | ||
*Dosage Forms: | *Dosage Forms: 10mg, 15mg, 20mg | ||
*Routes of Administration: | *Routes of Administration: | ||
*Common Trade Names: Xarelto | *Common Trade Names: Xarelto | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Thromboembolism/[[stroke]] prophylaxis=== | |||
*20mg PO QD | |||
===[[DVT]] Prophylaxis=== | |||
*10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established | |||
===[[DVT]]/[[PE]] Prophylaxis, recurrent=== | |||
*20mg PO once daily | |||
===[[DVT]]/[[PE]] Treatment=== | |||
*15mg twice daily x 21 days if CrCl ≥15<ref>Xarelto https://www.xareltohcp.com/dvt-pe/initial/dosing</ref> | |||
*20mg once daily starting day 22 if CrCl ≥15 | |||
===[[Atrial fibrillation]] and new stent<ref>Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.</ref>=== | |||
*Rivaroxaban 15 mg/day plus [[clopidogrel]] for 12 months post-stenting just as efficacious to current standard | |||
*Reduces clinically significant bleeds from ~27% to 17% as compared to [[warfarin]] plus DAPT | |||
==Special Populations== | ==Special Populations== | ||
| Line 19: | Line 28: | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Thromboembolism/[[stroke]] prophylaxis | *Thromboembolism/[[stroke]] prophylaxis | ||
**CrCl 15-50: 15mg | **CrCl 15-50: 15mg QD; CrCl <15: avoid use | ||
*[[DVT]] prophylaxis | *[[DVT]] prophylaxis | ||
**CrCl 30-50: caution advised; CrCl <30: avoid use | **CrCl 30-50: caution advised; CrCl <30: avoid use | ||
| Line 44: | Line 53: | ||
===Serious=== | ===Serious=== | ||
*[[Anticoagulant reversal for life-threatening bleeds|Bleeding, severe]] | *[[Anticoagulant reversal for life-threatening bleeds|Bleeding, severe]] | ||
**[[Andexanet alfa]] | |||
*Epidural/[[spinal hematoma]] | *Epidural/[[spinal hematoma]] | ||
*[[Thrombocytopenia]] | *[[Thrombocytopenia]] | ||
| Line 50: | Line 60: | ||
*[[Stevens-Johnson syndrome]] | *[[Stevens-Johnson syndrome]] | ||
*[[Hepatitis]] | *[[Hepatitis]] | ||
===Common=== | ===Common=== | ||
*Bleeding | *Bleeding | ||
*[[Back pain]] | *[[Back pain]] | ||
*[[Pruritus]] | *[[Pruritus]] | ||
*Elevated ALT | *Elevated ALT | ||
*[[Thrombocytopenia]] | *[[Thrombocytopenia]] | ||
| Line 63: | Line 74: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways | *Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Rivaroxaban]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
*[[Anticoagulant reversal for life-threatening bleeds]] | *[[Anticoagulant reversal for life-threatening bleeds]] | ||
*[[Andexanet alfa]] | |||
*[[Atrial fibrillation (main)]] | |||
==References== | ==References== | ||
*UpToDate | |||
*Epocrates | |||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 01:18, 25 March 2026
Administration
- Type: Anticoagulant, Factor Xa Inhibitor
- Dosage Forms: 10mg, 15mg, 20mg
- Routes of Administration:
- Common Trade Names: Xarelto
Adult Dosing
Thromboembolism/stroke prophylaxis
- 20mg PO QD
DVT Prophylaxis
- 10mg PO QD x35 days; Start: 6-10h post-op once hemostasis established
DVT/PE Prophylaxis, recurrent
- 20mg PO once daily
DVT/PE Treatment
- 15mg twice daily x 21 days if CrCl ≥15[1]
- 20mg once daily starting day 22 if CrCl ≥15
Atrial fibrillation and new stent[2]
- Rivaroxaban 15 mg/day plus clopidogrel for 12 months post-stenting just as efficacious to current standard
- Reduces clinically significant bleeds from ~27% to 17% as compared to warfarin plus DAPT
Special Populations
Renal Dosing
- Thromboembolism/stroke prophylaxis
- CrCl 15-50: 15mg QD; CrCl <15: avoid use
- DVT prophylaxis
- CrCl 30-50: caution advised; CrCl <30: avoid use
- DVT/PE prophylaxis, recurrent
- CrCl <30: avoid use
- DVT/PE treatment
- CrCl <30: avoid use
Hepatic Dosing
- Avoid Use In:
- Child-Pugh Class B or C
- Coagulopathy-assoc. hepatic disease
Contraindications
- Active major bleeding
- Hepatic impairment, Child-Pugh Class B or C
- Coagulopathy-assoc. hepatic disease
- CrCl <30 (DVT prophylaxis, recurrent DVT/PE prophylaxis, DVT/PE treatment use)
- CrCl <15 (thromboembolism/stroke prophylaxis use)
- Acute PE with hemodynamic instability
- Acute PE requiring thrombolysis or pulmonary embolectomy
Adverse Reactions
Serious
- Bleeding, severe
- Epidural/spinal hematoma
- Thrombocytopenia
- Agranulocytosis
- Hypersensitivity reaction
- Stevens-Johnson syndrome
- Hepatitis
Common
- Bleeding
- Back pain
- Pruritus
- Elevated ALT
- Thrombocytopenia
Pharmacology
- Half-life: 5-9 hours
- Metabolism: CYP450
- Excretion: 66% Urine, 28% Feces
Mechanism of Action
- Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Atrial fibrillation (main) | 20 mg daily with evening meal (reduced: 15 mg daily if CrCl 15-50) | Anticoagulation (NOAC) | PO | Adult |
| Pulmonary embolism | 15 mg PO BID x3 weeks, then 20 mg PO daily | Anticoagulation (DOAC) | PO | Adult |
See Also
References
- UpToDate
- Epocrates
- ↑ Xarelto https://www.xareltohcp.com/dvt-pe/initial/dosing
- ↑ Gibson CM et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016 Nov 14.